NunaBio Secures £6.5 Million to Scale Integrated DNA Manufacturing Platform for Gene Therapies

NunaBio's £6.5 million funding round signals a shift in how upstream DNA supply chains for gene therapies and advanced biologics may be structured, with direct consequences for CDMOs and QA teams managing novel modality programs under evolving GMP frameworks.

The UK-based biotech is deploying the capital to accelerate development of an integrated DNA manufacturing platform designed to support vaccines, gene therapies, and advanced biologics. Integrated platforms of this type consolidate multiple upstream process steps, which can reduce inter-site transfer risk and simplify the process validation burden that quality teams carry across distributed supply chains.

For CDMOs already navigating ICH Q10 pharmaceutical quality system requirements alongside client-specific regulatory filings, the emergence of dedicated DNA platform providers introduces both a sourcing option and a qualification challenge. Any new supplier of critical starting materials, particularly plasmid DNA or other genetic constructs used in viral vector manufacturing, requires robust supplier qualification programs and incoming material controls consistent with 21 CFR Part 211 and equivalent EU GMP expectations.

The gene therapy supply chain has faced persistent upstream bottlenecks, with plasmid DNA availability and quality consistency cited repeatedly as constraints on clinical and commercial scale-up. A platform approach that integrates design, synthesis, and manufacturing under a single quality system could address some of those pressure points, provided the platform achieves the sterility assurance levels and process consistency that regulatory agencies expect at each phase of development.

NunaBio has not disclosed specific technology details, partnership agreements, or a projected commercialisation timeline, leaving the operational readiness of the platform, and its fit within existing CDMO quality frameworks, to be assessed as the program advances.

The measurable checkpoint for quality and regulatory leads will be whether NunaBio's platform can demonstrate process validation data sufficient to support IND-enabling studies and, eventually, BLA or MAA submissions for gene therapy sponsors relying on its DNA supply.

Source: Media4Growth via Indian Pharma Post, 18 May 2026.